Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives

American Journal of Gastroenterology

Volumn 96, Issue 7, 2001, Pages 1977-1997

  Blam, Michael E ^a   Stein, Robert B ^a   Lichtenstein, Gary R ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BAY 103356; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE B4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PENTOXIFYLLINE; REACTIVE OXYGEN METABOLITE; THALIDOMIDE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BIOLOGICAL THERAPY; CLINICAL TRIAL; COUGHING; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FEVER; FRACTURE; HEADACHE; HEART FAILURE; HUMAN; NAUSEA; PATHOGENESIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; SINUSITIS; T LYMPHOCYTE; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; FORECASTING; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; MODELS, BIOLOGICAL; PENTOXIFYLLINE; RECEPTORS, TUMOR NECROSIS FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034936964     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02494-7     Document Type: Review

References (103)

1. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment
2. Medical therapy for Crohn's disease: State of the art
3. Novel therapies for inflammatory bowel disease
4. Mast cells are an important cellular source of tumour necrosis factor α in human intestinal tissue
5. 2
6. Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2
7. Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line
8. A major role for matrix metalloproteinases in T cell injury in the gut
9. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production
10. Differential cytokine expression by human intestinal epithelial cell lines: Regulated expression of interleukin 8
11. Renal allograft rejection: Expression and function of VCAM-1 on tubular epithelial cells
12. Effect of tumor necrosis factor-α and interferon-γ on the growth of a human salivary gland cell line
13. Synergistic effects of INF γ and tumour necrosis factor α on T84 cell function
14. Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa
15. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/BAX mucosal imbalance
16. Review article: Targeting TNFα as a key cytokine in the inflammatory processes of Crohn's disease - The mechanisms of action of infliximab
17. Human immunodeficiency virus infection and Crohn's disease: The role of the CD4 cell in inflammatory bowel disease
18. CD4 antibody treatment in patients with active Crohn's disease. A phase 1 dose finding study
19. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells
20. Tumor necrosis factor receptor-mediated signaling pathways
21. Tumour necrosis factor signal transduction
22. TNF activates NFκB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown
23. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins
24. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease
25. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes
26. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis
27. Cytokine gene transcription of human colonic intraepithelial lymphocytes cosimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicyclic acid
28. Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family
29. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
30. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease
31. Location of tumour nerosis factor α by immunohistochemistry in chronic inflammatory bowel disease
32. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridization
33. Quantitative PCR analysis of TNF-alpha, and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies
34. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
35. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
36. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment in inflammatory bowel disease
37. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
38. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice
39. IFN-gamma (IFN-γ)-, and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice
40. Combination therapy of pentoxyfilline and TNFα monoclonal antibody in dextra sulphate-induced mouse colitis
41. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha
42. Faecal tumour necrosis factor alpha in cottontop tamarin colitis
43. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
44. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
45. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
46. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-α antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease
47. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC)
48. Infliximab is an effective therapeutic agent for ulcerative colitis
49. Promising new agents for the treatment of inflammatory bowel disorders
50. Infliximab approved for use in Crohn's disease: A report on the FDA GI advisory committee conference
51. Infliximab (Remicade) for Crohn's disease
52. Treatment of fistulizing Crohn's disease
53. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctocolectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: Report of two cases
54. Treatment of severe esophageal Crohn's disease with Infliximab
55. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
56. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
57. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
58. Review article: Efficacy of infliximab in Crohn's disease - Induction and maintenance of remission
59. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
60. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone
61. Glucocorticoid treatment in ileal Crohn's disease: Relief of symptoms but not of endoscopically viewed inflammation
62. Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
63. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease
64. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
65. Endoscopic and histologic healing of (ileo-) colitis with azathioprine
66. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
67. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
68. Infliximab for the treatment of fistulas in patients with Crohn's disease
69. Treatment of fistulas in Crohn's disease with infliximab
70. Successful management of Crohn's disease of the ileoanal pouch with infliximab
71. Review article: Safety of infliximab in clinical trials
72. Long term safety of infliximab
73. The relationship between infliximab treatment and lymphoma in Crohn's disease
74. CDP 571. Anti-TNF monoclonal antibody, BAY 103356
75. Treatment of ulcerative colitis with an engineered human anti-TNF α antibody CDP571
76. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
77. A randomized controlled trial of CDP571, a humanized antibody to TNFα, in moderately to severely active Crohn's disease
78. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
79. Selected summary: A controlled trial of anti-tumor necrosis factor α antibody for Crohn's disease
80. Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel
81. Etanercept (TNF receptor fusion protein, enbrel) is effective, and well tolerated in active refractory Crohn's disease. Results of a single center pilot trial
82. Curative effects of phosphodiesterase 4 inhibitors in dextran sulfate sodium-induced colitis in the rat
83. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice
84. Selective inhibition of phosphodiesterase type IV ameliorates chronic colitis and prevents intestinal fibrosis
85. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease
86. Thalidomide in oral Crohn's disease refractory to conventional medical treatment
87. Thalidomide in Crohn's disease
88. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
89. Inhibition of IL-12 production by thalidomide
90. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis
91. Protein kinase C-dependent effects on leukocyte migration of thalidomide
92. Thalidomide is an inhibitor of angiogenesis
93. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
94. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
95. Open labeled pilot study of thalidomide (THAL) as a novel therapy for medically resistant ulcerative colitis
96. New life in a sleeper: Thalidomide and Crohn's disease
97. Frequency of glucocorticoid resistance and dependency in Crohn's disease
98. Review article: The medical management of Crohn's disease
99. Medical therapies for inflammatory bowel disease
100. Duration of response following cessation of infliximab therapy for active or fistulizing Crohn's disease
101. Non-smoking, and concurrent immunosuppressive use are predictors of response to infliximab in patients with Crohn's disease
102. The response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease
103. Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody